Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been ...
SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...
Takeda (TSE:4502/NYSE:TAK) today announced that the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older, as prescribed, who are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback